Autolus Therapeutics plc (AUTL)Healthcare | Biotechnology | London, United Kingdom | NasdaqGS
1.69 USD
+0.07
(4.321%)
⇧
(Oct. 14, 2026, 4 p.m.
EDT)
After hours: 1.65 -0.04 (-0.040%) ⇩ (Oct. 14, 2026, 6:15 p.m. EDT) |
Hot Take ↕ | Oct. 10, 2026, 5:33 a.m. EDT
The investment case here is a stark dichotomy between a fundamentally broken biotech company and a speculative vehicle fueled entirely by options flow. Fundamentally, the business is deteriorating; the stock has lost over 93% of its value over the last seven years, with gross margins in negative territory and no dividend to cushion the blow. While analysts project a recovery to nearly $9, the underlying metrics—negative free cash flow, massive debt relative to equity, and a history of consecutive annual declines—suggest the market is pricing in a miracle rather than a turnaround. The recent price action shows the stock struggling to hold above its 50-day average, indicating weak immediate momentum. However, the options data tells a different story for the short term: traders are positioning aggressively for a breakout, with call open interest dwarfing put activity. This creates a high-risk, high-reward scenario where the stock could spike on any positive clinical news, but the lack of downside protection in the options chain leaves buyers exposed to a continued grind lower if the catalyst fails to materialize. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.330655 |
| AutoETS | 0.337467 |
| AutoARIMA | 0.337472 |
| AutoTheta | 0.355415 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 40% |
| H-stat | 0.98 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.076 |
| Excess Kurtosis | 0.13 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 491.471 |
| Revenue per Share | 0.441 |
| Market Cap | 449,814,720 |
| Forward P/E | -2.65 |
| Beta | 2.14 |
| Profit Margins | -238.65% |
| Website | https://www.autolus.com |
As of Oct. 10, 2026, 5:33 a.m. EDT: Speculators are overwhelmingly bullish on the upside, evidenced by massive open interest in out-of-the-money calls (strikes $2.50 and $5.00) compared to virtually zero put volume. This creates a heavy gamma exposure that could fuel a sharp rally if the stock breaks above the $2.00 resistance, though the lack of protective puts suggests a 'naked' long bias.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.03571427 |
| Address1 | The Mediaworks |
| Address2 | 191 Wood Lane White City |
| All Time High | 53.24 |
| All Time Low | 1.105 |
| Ask | 2.06 |
| Ask Size | 2 |
| Average Analyst Rating | 1.1 - Strong Buy |
| Average Daily Volume10 Day | 1,672,960 |
| Average Daily Volume3 Month | 2,089,446 |
| Average Volume | 2,089,446 |
| Average Volume10Days | 1,672,960 |
| Beta | 2.144 |
| Bid | 1.26 |
| Bid Size | 2 |
| Book Value | 0.281 |
| City | London |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United Kingdom |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.69 |
| Current Ratio | 4.886 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 1.7 |
| Day Low | 1.6 |
| Debt To Equity | 491.471 |
| Display Name | Autolus Therapeutics |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,786,451,400 |
| Earnings Call Timestamp Start | 1,786,451,400 |
| Earnings Timestamp | 1,786,451,400 |
| Earnings Timestamp End | 1,794,832,200 |
| Earnings Timestamp Start | 1,794,832,200 |
| Ebitda | -236,571,008 |
| Ebitda Margins | -2.01526 |
| Enterprise To Ebitda | -2.604 |
| Enterprise To Revenue | 5.247 |
| Enterprise Value | 615,996,672 |
| Eps Current Year | -0.79743 |
| Eps Forward | -0.63787 |
| Eps Trailing Twelve Months | -1.06 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 2.0591 |
| Fifty Day Average Change | -0.36909986 |
| Fifty Day Average Change Percent | -0.17925301 |
| Fifty Two Week Change Percent | -3.5714269 |
| Fifty Two Week High | 2.58 |
| Fifty Two Week High Change | -0.88999987 |
| Fifty Two Week High Change Percent | -0.3449612 |
| Fifty Two Week Low | 1.175 |
| Fifty Two Week Low Change | 0.5150001 |
| Fifty Two Week Low Change Percent | 0.438298 |
| Fifty Two Week Range | 1.175 - 2.58 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,529,674,200,000 |
| Float Shares | 102,919,731 |
| Forward Eps | -0.63787 |
| Forward P E | -2.6494427 |
| Free Cashflow | -201,190,000 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 752 |
| Fullday Change | 0.029999971 |
| Fullday Change Percent | 1.85185 |
| Fullday Price | 1.69 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | -0.74603 |
| Gross Profits | -87,577,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.18086 |
| Held Percent Institutions | 0.63423 |
| Implied Shares Outstanding | 266,162,540 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor. It also develops obe-cel, which is in phase 1 to treat systemic lupus erythematosus, progressive multiple sclerosis, B-NHL and CLL, and CNS lymphoma; obe-cel, which is in phase 2 to treat pediatric B-ALL and lupus nephritis; AUTO1/22 to treat pediatric B-ALL, which is phase 1; AUTO8, which is in phase 1 to treat multiple myeloma and light chain amyloidosis; AUTO4/5, which is in preclinical stage to treat peripheral TCL; AUTO6NG, which is in phase 1 to treat neuroblastoma; and AUTO9, which is in preclinical stage to treat acute myeloid leukemia. The company was incorporated in 2014 and is headquartered in London, the United Kingdom. |
| Long Name | Autolus Therapeutics plc |
| Market | us_market |
| Market Cap | 449,814,720 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_562879769 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -280,156,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 519,016,953 |
| Number Of Analyst Opinions | 8 |
| Open | 1.61 |
| Operating Cashflow | -225,608,000 |
| Operating Margins | -0.95949 |
| Phone | 44 20 3829 6230 |
| Post Market Change | -0.04000008 |
| Post Market Change Percent | -2.3668687 |
| Post Market Price | 1.65 |
| Post Market Time | 1,792,016,109 |
| Previous Close | 1.62 |
| Price Eps Current Year | -2.1193085 |
| Price Hint | 4 |
| Price To Book | 6.0142355 |
| Price To Sales Trailing12 Months | 3.8317976 |
| Profit Margins | -2.3865402 |
| Quick Ratio | 4.059 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.11111 |
| Region | US |
| Regular Market Change | 0.0700001 |
| Regular Market Change Percent | 4.32099 |
| Regular Market Day High | 1.7 |
| Regular Market Day Low | 1.6 |
| Regular Market Day Range | 1.6 - 1.7 |
| Regular Market Open | 1.61 |
| Regular Market Previous Close | 1.62 |
| Regular Market Price | 1.69 |
| Regular Market Time | 1,792,008,001 |
| Regular Market Volume | 2,590,099 |
| Return On Assets | -0.25437 |
| Return On Equity | -1.32995 |
| Revenue Growth | 1.184 |
| Revenue Per Share | 0.441 |
| Sand P52 Week Change | 0.1570785 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 266,162,540 |
| Shares Percent Shares Out | 0.031600002 |
| Shares Short | 8,400,156 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 9,084,567 |
| Short Name | Autolus Therapeutics plc |
| Short Percent Of Float | 0.048699997 |
| Short Ratio | 5.29 |
| Source Interval | 15 |
| Symbol | AUTL |
| Target High Price | 11.0 |
| Target Low Price | 5.0 |
| Target Mean Price | 8.725 |
| Target Median Price | 9.5 |
| Total Cash | 201,630,000 |
| Total Cash Per Share | 0.758 |
| Total Debt | 367,812,000 |
| Total Revenue | 117,390,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.06 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.678025 |
| Two Hundred Day Average Change | 0.01197505 |
| Two Hundred Day Average Change Percent | 0.007136395 |
| Type Disp | Equity |
| Volume | 2,590,099 |
| Website | https://www.autolus.com |
| Zip | W12 7FP |